title: Lectin binding and effects in culture on human cancer and non-cancer cell lines: examination of issues of interest in drug design strategies.
abstract: By using a non-cancer and a cancer cell line originally from the same tissue (colon), coupled with testing lectins for cell binding and for their effects on these cell lines in culture, this study describes a simple multi-parameter approach that has revealed some interesting results that could be useful in drug development strategies. Two human cell lines, CCL-220/Colo320DM (human colon cancer cells, tumorigenic in nude mice) and CRL-1459/CCD-18Co (non-malignant human colon cells) were tested for their ability to bind to agarose microbeads derivatized with two lectins, peanut agglutinin (Arachis hypogaea agglutinin, PNA) and Dolichos biflorus agglutinin (DBA), and the effects of these lectins were assessed in culture using the MTT assay. Both cell lines bound to DBA-derivatized microbeads, and binding was inhibited by N-acetyl-D-galactosamine, but not by L-fucose. Neither cell line bound to PNA-derivatized microbeads. Despite the lack of lectin binding using the rapid microbead method, PNA was mitogenic in culture at some time points and its mitogenic effect displayed a reverse-dose response. This was also seen with effects of DBA on cells in culture. While this is a simple study, the results were statistically highly significant and suggest that: (1) agents may not need to bind strongly to cells to exert biological effects, (2) cell line pairs derived from diseased and non-diseased tissue can provide useful comparative data on potential drug effects and (3) very low concentrations of potential drugs might be initially tested experimentally because reverse-dose responses should be considered.
authors: Department of Biology and Center for Cancer and Developmental Biology, California State University Northridge, 18111 Nordhoff St. Northridge, CA 91330-8303, USA.
authors: Karineh
authors: K
authors: Petrossian
authors: Lisa R
authors: LR
authors: Banner
authors: Steven B
authors: SB
authors: Oppenheimer
mesh_terms: D001681:Biological Assay / Q000379:methods; D002460:Cell Line; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D015195:Drug Design; D006801:Humans; D037102:Lectins / Q000378:metabolism* / Q000493:pharmacokinetics; D037121:Plant Lectins / Q000378:metabolism / Q000493:pharmacokinetics; D011485:Protein Binding
chemical_list: D037102:Lectins; D037121:Plant Lectins; C036554:dolichos biflorus agglutinin
references: J Immunol. 2000 Aug 15;165(4):2156-64
references: 10925302
references: Glycobiology. 2006 Jul;16(7):594-601
references: 16571666
references: Int J Pharm. 2001 Jun 19;221(1-2):35-47
references: 11397565
references: Glycobiology. 2001 Jul;11(7):587-92
references: 11447138
references: Trends Cell Biol. 2001 Oct;11(10):406-12
references: 11567873
references: Acta Histochem. 2002;104(1):99-106
references: 11993857
references: Cancer Metastasis Rev. 2001;20(3-4):245-77
references: 12085965
references: Acta Histochem. 2002;104(3):217-23
references: 12389735
references: Cancer Chemother Pharmacol. 2003 Jun;51(6):451-8
references: 12695857
references: Anticancer Res. 2003 Mar-Apr;23(2B):1197-206
references: 12820371
references: Adv Drug Deliv Rev. 2004 Mar 3;56(4):425-35
references: 14969751
references: Adv Drug Deliv Rev. 2004 Mar 3;56(4):459-80
references: 14969753
references: Adv Drug Deliv Rev. 2004 Mar 3;56(4):491-509
references: 14969755
references: Anticancer Res. 2004 Mar-Apr;24(2C):1187-92
references: 15154645
references: Cancer Res. 1979 Dec;39(12):4914-24
references: 498117
references: Microbiol Rev. 1984 Sep;48(3):199-221
references: 6436655
references: Int J Cancer. 1988 Feb 15;41(2):287-96
references: 3338874
references: Pathology. 1988 Apr;20(2):157-65
references: 3211593
references: Virchows Arch A Pathol Anat Histopathol. 1989;415(4):347-56
references: 2505446
references: Exp Pathol. 1991;41(4):175-83
references: 2070840
references: J Natl Cancer Inst. 1992 Sep 16;84(18):1410-6
references: 1512792
references: J Cell Biochem Suppl. 1992;16G:103-9
references: 1469891
references: Gastroenterology. 1994 Jan;106(1):117-24
references: 8276172
references: Glycobiology. 1993 Oct;3(5):447-53
references: 8286857
references: Int J Cancer. 1994 May 15;57(4):561-7
references: 7514154
references: J Pharmacol Toxicol Methods. 1995 Feb;33(1):1-10
references: 7727802
references: Acta Histochem. 1995 Jan;97(1):89-97
references: 7771187
references: Acta Histochem. 1995 Oct;97(4):373-82
references: 8607287
references: Acta Histochem. 1996 Nov;98(4):441-51
references: 8960308
references: Gut. 1997 Feb;40(2):253-61
references: 9071941
references: J Neurooncol. 1997 Sep;34(2):111-22
references: 9210057
references: Melanoma Res. 1997 Oct;7(5):353-63
references: 9429218
references: J Control Release. 1998 Nov 13;55(2-3):131-42
references: 9795030
references: Gut. 1999 May;44(5):709-14
references: 10205210
references: J Cancer Res Clin Oncol. 1999;125(5):275-85
references: 10359132
references: Anticancer Res. 1999 Mar-Apr;19(2A):1245-8
references: 10368683
references: Acta Histochem. 1999 Jul;101(3):263-70
references: 10443289
references: Acta Histochem. 1999 Jul;101(3):271-9
references: 10443290
references: J Drug Target. 2005 May;13(4):251-7
references: 16051537
references: Acta Histochem. 2005;107(5):335-44
references: 16181664
references: Acta Histochem. 2006;107(6):411-20
references: 16414103
references: J Cell Physiol. 2001 Feb;186(2):282-7
references: 11169464